Title of the clinical trial,Trial number,Overall trial status,Countries where the trial is taking place (EU country code),Overall start date of the trial (in the EU),Overall end date of the trial (in the EU),Decision date,Conditions,Therapeutic area,Recruitment status,Sponsor/Co-Sponsors,Sponsor type,Trial phase,End point,Product,Age group,Last updated
Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study),2022-502604-67-00,"Ongoing, recruitment ended","DK:Ongoing, recruitment ended, ES:Ongoing, recruitment ended, SE:Ongoing, recruitment ended, NO:Ongoing, recruitment ended",2019-12-20,, DK:20/02/2023  ES:20/02/2023  SE:20/02/2023  NO:17/02/2023,Malignant pleural mesothelioma (MPM),"Diseases [C] - Neoplasms [C04],Diseases [C] - Respiratory Tract Diseases [C08]","DK:Ended, ES:Ended, SE:Ended, NO:Ended",Oslo University Hospital Hf,Hospital/Clinic/Other health care facility,Phase II and Phase III (Integrated),"Overall survival (OS), objective response rate (ORR), disease control rate (DCR), time to response (TTR) and duration of response (DOR)., European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) and it's Lung Cancer Module (LC13) scores., Adverse events (AEs)., Study drug discontinuations due to AEs.","Leukine, YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.","65+ years, 18-64 years, 65+ years, 18-64 years, 65+ years",
Nivolumab in combination with cisplatin and 5-fluorouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carcinoma,2022-500676-59-00,"Ongoing, recruiting","DE:Ongoing, recruiting",2022-12-06,, DE:30/05/2023,EBV-positive nasopharyngeal carcinoma,Diseases [C] - Neoplasms [C04],DE:Ongoing,Gpoh Gemeinnützige GmbH,Pharmaceutical company,Therapeutic exploratory (Phase II),"Event-free survival (EFS), Overall survival (OS), Safety and tolerability: adverse events (AEs), serious adverse events (SAEs), Efficacy based on PD-L1 expression in tumor tissue","CARBOPLATIN, NIVOLUMAB, INTERFERON BETA-1A, GEMCITABINE","18-64 years, 18-64 years, 0-17 years, 0-17 years, 0-17 years, 0-17 years",
METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer – Shaping Anti-Tumor Immunity by Oxaliplatin,2022-500027-76-00,"Ongoing, recruiting","NO:Ongoing, recruiting",2022-10-05,, NO:21/03/2023,Colorectal cancer,Diseases [C] - Neoplasms [C04],NO:Ongoing,Akershus University Hospital,Hospital/Clinic/Other health care facility,Therapeutic exploratory (Phase II),"Safety: incidence of adverse events, as reported according to CTCAE v5.0, recorded on onboing basis and summarized at every visit., Tolerability: adverse event grading, as assessed by CTCAE v5.0, recorded on onboing basis and summarized at every visit., Objective response rate: the percentage of patients with a confirmed complete or partial response., Duration of response: the time from the first documentation of a complete or partial response to disease progression on active therapy., Secondary surgical curative-intent resection rate: the percentage of patients with a confirmed resection of metastatic disease with microscopically free margin (R0)., Overall survival: the time from study enrollment to death of any cause.","Adrenalin Aguettant 1 mg/ml injeksjonsvæske, oppløsning i ferdigfylt sprøyte, Fluorouracil Accord 50 mg/ml injeksjons-/infusjonsvæske, oppløsning, OPDIVO 10 mg/mL concentrate for solution for infusion., Ondansetron Bluefish 8 mg tabletter, filmdrasjerte, Solu-Cortef 250 mg pulver og væske til injeksjonsvæske, oppløsning i tokammerhetteglass, Dexamethasone Krka 4 mg tabletter, Metoclopramide Accord 10 mg tabletter, Kalsiumfolinat Pfizer 10 mg/ml injeksjonsvæske, oppløsning, Oxaliplatin Fresenius Kabi 5 mg/ml konsentrat til infusjonsvæske, oppløsning, Paracet 1 g tabletter","18-64 years, 65+ years, 18-64 years",
"A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma",2022-500630-29-00,"Ongoing, recruiting","AT:Ongoing, recruitment ended, BE:Ongoing, not yet recruiting, DK:Ongoing, not yet recruiting, FR:Ongoing, recruitment ended, DE:Ongoing, recruitment ended, GR:Ongoing, not yet recruiting, IE:Ongoing, not yet recruiting, IT:Ongoing, not yet recruiting, RO:Ongoing, recruiting, ES:Ongoing, recruitment ended, SE:Ongoing, not yet recruiting, NL:Ongoing, not yet recruiting, PL:Ongoing, recruitment ended",2016-05-06,, DK:11/08/2022  FR:12/08/2022  DE:12/08/2022  GR:12/08/2022  IE:11/08/2022  IT:11/08/2022  RO:12/08/2022  SE:12/08/2022,Subjects with High Risk Invasive Urothelial Carcinoma,Diseases [C] - Neoplasms [C04],"AT:Ended, BE:Pending, DK:Pending, FR:Ended, DE:Ended, GR:Pending, IE:Pending, IT:Pending, RO:Ongoing, ES:Ended, SE:Pending, NL:Pending, PL:Ended",Bristol-Myers Squibb International Corporation,Pharmaceutical company,Therapeutic confirmatory  (Phase III),"To compare Non-Urothelial Tract Recurrence Free Survival (NUTRFS) for nivolumab versus placebo in subjects with tumors expressing PD-L1 (>= 1% membranous staining in tumor cells) and all randomized subjects, To compare the Disease Specific Survival (DSS) for nivolumab and placebo in subjects with tumors expressing PD-L1 (>=1% membranous staining in tumor cells) and all randomized subjects, To compare the Overall Survival (OS) for nivolumab versus placebo in subjects with tumors expressing PD-L1 (>=1% membranous staining in tumor cells) and all randomized subjects","OPDIVO 10 mg/mL concentrate for solution for infusion., 0.9% sodium chloride injection. Solution for injection., 5% Dextrose injection, MDX1106 ONO-4538","18-64 years, 65+ years, 18-64 years",
Immunotherapy in patients with early dMMR rectal cancer. A Danish DCCG phase II trial,2022-500646-14-00,"Ongoing, not yet recruiting","DK:Ongoing, not yet recruiting",2023-01-31,, DK:07/11/2022,cancer,Diseases [C] - Neoplasms [C04],DK:Pending,Odense University Hospital,Hospital/Clinic/Other health care facility,Therapeutic exploratory (Phase II),"Number of patients with complete biological response after 1 or 2 cycles of immunotherapy., Number of patients without any sign of recurrence after 12 months., Response rate according to mrTRG (24)., Adverse events., Correlation between bio-markers (ctDNA and CEA) and outcome., Quality of life (EORCT QLQ-C30 and EORCT QLQ-CR29).","OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion","65+ years, 18-64 years, 18-64 years",
"Calcium electroporation in combination with irreversible electroporation and immunotherapy in patients with pMMR metastatic colorectal cancer - A prospective, phase 2 study",2022-500045-25-00,"Authorised, not started","DK:Authorised, not started",,,,Colorectal cancer,Diseases [C] - Neoplasms [C04],DK:Pending,Zealand University Hospital,Hospital/Clinic/Other health care facility,Therapeutic exploratory (Phase II),"To evaluate the systemic response, measured by biopsy data from a metastasis not treated with IRE, To evaluate the efficacy of Ca-EP and IRE in combination with pembrolizumab, To evaluate tumor response per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, To evaluate tumor response by dynamic contrast enhanced ultra sound (DCE-US), To evaluate the phenotypic change of the TILs from the primary tumor by flow cytometry, To evaluate progression free survival, To evaluate overall survival, To evaluate quality of life (by questionnaire EORTC QLQ-C30)","CALCIUM CHLORIDE HEXAHYDRATE, KEYTRUDA 25 mg/mL concentrate for solution for infusion","65+ years, 18-64 years",